Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Czechia

European Research Council grant · Running

FitSleep Fabricating Non-Invasive Temporal Interference Devices for Obstructive Sleep Apnea which Electrically activate the Hypoglossal Nerve

Coordinator
Masarykova univerzita, Czechia
Runs
1 May 2024 to 31 October 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101157945

What the project is doing

In the project's own words, from its summary on CORDIS.

Obstructive sleep apnea (OSA) is a highly prevalent disorder characterized by episodes of decreased or absent inspiratory airflow during sleep. OSA is the worlds second-most common sleep disorder, plaguing over 1 billion patients worldwide with relentless, disruptive periods of restricted airflow during sleep. This can have dramatic effects, ranging from excessive daytime sleepiness to other comorbidities such as stroke, hypertension or depression.

The effects of this disorder are pervasive and far-reaching, as diminished sleep quality eventually reduces general quality of life. Positive airway pressure (PAP) delivered through a tight-fitting mask is currently the most advanced technique for preventing airway collapse or airway narrowing during sleep, and is considered the primary treatment option for patients with moderate to severe OSA. However, despite improvements in quieter pumps and more comfortable masks, this approach has several disadvantages and patients very often struggle to comply with the therapy.

We have recently shown that a non-invasive form of HNS can be effective in treating OSA patients by using temporal interference (TI) , a new non-invasive electrical stimulation technology which has been successfully advanced also for other clinical applications by the PI. Our device revolutionizes sleep apnea treatment with the efficacy of upper airway stimulation, without requiring surgery. Our proprietary new technology generates comfortable electrical fields which activate the tongue muscle and open airways.

Its effectiveness is comparable to the best in market, while remaining non-invasive and financially accessible. FitSleep is an essential part of our exploitation strategy, which will ensure we advance the technology from TRL4 (currently) to TRL5. This will give us an ideal position for a subsequent EIC Transition application.

Topics

Who is involved

OrganisationCityCountryRole
Masarykova univerzitaBrnoCzechiaCoordinator
Somnial Technologies SroBrno StredCzechiaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI